Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 11/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 10/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 10/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20243856 | 1.00 | GNAO1 (0.37) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL27279285 | 0.98 | GNAO1 (0.38) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL22068564 | 0.98 | GNAO1 (0.38) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL21677540 | 0.98 | GNAO1 (0.38) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL21214015 | 0.98 | GNAO1 (0.38) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL18799744 | 0.98 | GNAO1 (0.38) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL26334665 | 0.96 | GNAO1 (0.35) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL21008273 | 0.94 | GNAI3 (0.32) | GNAO1GNAI3GNAI1NPC1 | |
| SCHEMBL21677324 | 0.91 | GNAO1 (0.36) | GNAO1GNAI3GNAI1NPC1TP53 | |
| SCHEMBL22024185 | 0.90 | TSHR (0.38) | GNAO1GNAI3GNAI1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10792651-B2 | Synthesis and characterization of Ru alkylidene complexes | UMICORE AG & CO. KG (DE) | 2020-10-06 | — | — | US | disclosed |
| US-20200290977-A1 | Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof | LA JOLLA INSTITUTE OF ALLERGY & IMMUNOLOGY | 2020-09-17 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10647683-B2 | Hsp70 modulators and methods for making and using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200038851-A1 | SYNTHESIS AND CHARACTERIZATION OF RU ALKYLIDENE COMPLEXES | UMICORE AG & CO. KG (DE) | 2020-02-06 | — | — | US | disclosed |
| US-20190241526-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2019-08-08 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241526-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | HSPA2, HSP90AA1, HSP90AB1 | GNAO1 3573/4885GNAI3 1665/4885GNAI1 1617/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | GNAO1 763/4885GNAI3 861/4885GNAI1 530/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | GNAO1 763/4885GNAI3 861/4885GNAI1 530/4885 |
| US-20200290977-A1 | Inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase and Uses Thereof | ACP1, PTPRCAP, PTPA | GNAO1 2514/4885GNAI3 1061/4885GNAI1 652/4885 |
| US-20200038851-A1 | SYNTHESIS AND CHARACTERIZATION OF RU ALKYLIDENE COMPLEXES | PORCN, ORC3, COASY | GNAO1 3607/4885GNAI3 3520/4885GNAI1 3716/4885 |
| US-10647683-B2 | Hsp70 modulators and methods for making and using the same | HSPA2, HSP90AA1, HSP90AB1 | GNAO1 3573/4885GNAI3 1665/4885GNAI1 1617/4885 |
| US-10792651-B2 | Synthesis and characterization of Ru alkylidene complexes | PORCN, ORC3, COASY | GNAO1 3607/4885GNAI3 3520/4885GNAI1 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.